Artiva Biotherapeutics Statistics
Total Valuation
ARTV has a market cap or net worth of $198.22 million. The enterprise value is -$111.71 million.
| Market Cap | 198.22M |
| Enterprise Value | -111.71M |
Important Dates
The last earnings date was Tuesday, November 10, 2026, after market close.
| Earnings Date | Nov 10, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
ARTV has 49.43 million shares outstanding. The number of shares has increased by 43.62% in one year.
| Current Share Class | 49.43M |
| Shares Outstanding | 49.43M |
| Shares Change (YoY) | +43.62% |
| Shares Change (QoQ) | +29.91% |
| Owned by Insiders (%) | 4.43% |
| Owned by Institutions (%) | 40.45% |
| Float | 20.15M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 0.61 |
| P/TBV Ratio | 0.62 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 19.88, with a Debt / Equity ratio of 0.03.
| Current Ratio | 19.88 |
| Quick Ratio | 19.55 |
| Debt / Equity | 0.03 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -43.61% and return on invested capital (ROIC) is -27.93%.
| Return on Equity (ROE) | -43.61% |
| Return on Assets (ROA) | -26.74% |
| Return on Invested Capital (ROIC) | -27.93% |
| Return on Capital Employed (ROCE) | -32.22% |
| Weighted Average Cost of Capital (WACC) | 18.16% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$732,201 |
| Employee Count | 134 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +0.75% in the last 52 weeks. The beta is 2.68, so ARTV's price volatility has been higher than the market average.
| Beta (5Y) | 2.68 |
| 52-Week Price Change | +0.75% |
| 50-Day Moving Average | 6.66 |
| 200-Day Moving Average | 8.00 |
| Relative Strength Index (RSI) | 22.90 |
| Average Volume (20 Days) | 1,360,255 |
Short Selling Information
The latest short interest is 2.74 million, so 5.54% of the outstanding shares have been sold short.
| Short Interest | 2.74M |
| Short Previous Month | 2.30M |
| Short % of Shares Out | 5.54% |
| Short % of Float | 13.59% |
| Short Ratio (days to cover) | 5.00 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -105.21M |
| Pretax Income | -98.12M |
| Net Income | -98.12M |
| EBITDA | -102.43M |
| EBIT | -105.21M |
| Earnings Per Share (EPS) | -$2.80 |
Balance Sheet
The company has $319.10 million in cash and $9.17 million in debt, with a net cash position of $309.93 million or $6.27 per share.
| Cash & Cash Equivalents | 319.10M |
| Total Debt | 9.17M |
| Net Cash | 309.93M |
| Net Cash Per Share | $6.27 |
| Equity (Book Value) | 320.72M |
| Book Value Per Share | 6.51 |
| Working Capital | 309.84M |
Cash Flow
In the last 12 months, operating cash flow was -$84.48 million and capital expenditures -$2.12 million, giving a free cash flow of -$86.60 million.
| Operating Cash Flow | -84.48M |
| Capital Expenditures | -2.12M |
| Depreciation & Amortization | 2.78M |
| Net Borrowing | -79,000 |
| Free Cash Flow | -86.60M |
| FCF Per Share | -$1.75 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
ARTV does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -43.62% |
| Shareholder Yield | -43.62% |
| Earnings Yield | -69.83% |
| FCF Yield | -43.69% |
Analyst Forecast
The average price target for ARTV is $20.75, which is 417.46% higher than the current price. The consensus rating is "Buy".
| Price Target | $20.75 |
| Price Target Difference | 417.46% |
| Analyst Consensus | Buy |
| Analyst Count | 6 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
| Graham Formula Value | n/a |
| Graham Formula Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 2 |